Post by Harbour BioMed

Great news to share as we continue to strengthen our scientific leadership! We are delighted to announce that Dr. Dhaval Patel has joined Harbour BioMed as a Scientific Advisor. 🎉 🎉 Dr. Patel brings a remarkable track record of therapeutic innovation spanning over two decades—bridging top-tier academia and industry leadership. He is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology. Prior to joining Sana Biotechnology, Dr. Patel served as EVP and CSO at UCB, where he and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®), and zilucoplan (Zilbrysq®). Before that, he spent 10 years at Novartis as Head of Research at NIBR Europe, contributing to an extraordinary roster of approved medicines in multiple indications, including: 🔹 Secukinumab (Cosentyx®) 🔹 Fingolimod (Gilenya®) 🔹 Siponimod (Mayzent®) 🔹 Canakinumab (Ilaris®) 🔹 Everolimus (Zortress®/Certican®, Afinitor®) 🔹 Leniolisib (Joenja®) 🔹 Iptacopan (Fabhalta®) Dr. Patel’s journey began in academia as an Eminent Professor of Medicine, Chief of Rheumatology, and Director of the Thurston Arthritis Research Center at UNC Chapel Hill. He also holds B.S., M.D., and Ph.D. from Duke University and is board certified in internal medicine, rheumatology, and allergy & immunology. 🔬 Dr. Patel’s outstanding combination of deep immunological science, proven drug development success, and board-level strategic insight will be a tremendous asset to us. We look forward to working closely with him to advance our innovative programs from discovery through development and ultimately to patients. 🤝 🤝 🔗 Read the full press release here: https://lnkd.in/gh3ad3eP #Immunology #DrugDiscovery #AntibodyTherapeutics #Leadership #ScientificAdvisoryBoard #Innovation